Industry news that matters to you.  Learn more

Caprion Announces Agreement To In-License Xpresys Lung From Indi For Canadian Commercialization

Reading time: 2 – 3 minutes

Caprion recently announced an exclusive agreement to in-license Xpresys Lung in Canada from Indi (Integrated Diagnostics®). Xpresys Lung is a breakthrough, molecular diagnostic blood test that assists with the management of indeterminate lung nodules. The clinical laboratory developed test is currently only available in the United States and provides physicians with objective information to identify nodules with a high probability of being benign – potentially reducing unnecessary invasive procedures, which may be risky for the patient and costly to the healthcare system.

“Xpresys Lung is an important addition to our clinical laboratory service business and enables us to provide new diagnostic tools for physicians in Canada which may aid them in reducing unnecessary invasive procedures for benign lung nodules — generating economic efficiencies for our healthcare system,” said Martin LeBlanc, chief executive officer, Caprion. “We look forward to offering physicians and patients access to this cutting-edge molecular diagnostic test from our clinical laboratory in Montreal.”

“Indi’s agreement enables Caprion to deploy our proven, standardized proteomic Xpresys Lung laboratory service in their own facility, equivalent to our CLIA laboratory in the U.S.,” said Albert A. Luderer, Ph.D., chief executive officer, Indi.

The agreement marks the continuation of a long-standing collaboration between Indi and Caprion, which began with Caprion as an early partner of Indi in the proteomics clinical discovery of Xpresys Lung.

Caprion will hold the exclusive rights to market and commercialize Xpresys Lung in Canada, beginning with Quebec. Caprion will pay Indi royalties and several milestone payments. Exact financial terms of the agreement were not disclosed.

Caprion has received support for its Canadian Xpresys Lung commercial efforts from the Government of Quebec as part of the Personalized Medicine Partnership for Cancer (PMPC), a public-private partnership led by Caprion and focused on clinical biomarkers and personalized healthcare solutions to improve the outcome and cost-efficiency of healthcare services provided to cancer patients in the province of Quebec (www.pmpc-org.com).

Source: PR Newswire